Ageing, oestrogen, platelets and thrombotic risk

Virginia M Miller, Muthuvel Jayachandran, Whyte G. Owen

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

1. Adverse thrombotic cardiovascular events increase in women coincident with the onset of menopause. 2. Age past menopause may be an important variable in defining the benefit/risk of hormone treatments. 3. Few studies have examined hormonal status as a variable of ageing using a polygenomic approach of both humoral and cellular components of the coagulation system. 4. Longitudinal studies of a global set of platelet functions that define procoagulant activity (i.e. adhesion, aggregation, secretion and thrombin production) in individuals with documented hormonal status are needed to better understand how hormonal changes associated with ageing impact thrombotic risk.

Original languageEnglish (US)
Pages (from-to)814-821
Number of pages8
JournalClinical and Experimental Pharmacology and Physiology
Volume34
Issue number8
DOIs
StatePublished - Aug 2007

Fingerprint

Menopause
Estrogens
Blood Platelets
Thrombin
Longitudinal Studies
Hormones
Therapeutics

Keywords

  • 17β-oestradiol
  • Energy metabolism
  • Kronos Early Estrogen Prevention Study (KEEPS)
  • Mitochondria
  • Women's Health Initiative

ASJC Scopus subject areas

  • Physiology
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Ageing, oestrogen, platelets and thrombotic risk. / Miller, Virginia M; Jayachandran, Muthuvel; Owen, Whyte G.

In: Clinical and Experimental Pharmacology and Physiology, Vol. 34, No. 8, 08.2007, p. 814-821.

Research output: Contribution to journalArticle

Miller, Virginia M ; Jayachandran, Muthuvel ; Owen, Whyte G. / Ageing, oestrogen, platelets and thrombotic risk. In: Clinical and Experimental Pharmacology and Physiology. 2007 ; Vol. 34, No. 8. pp. 814-821.
@article{2c9dbb53092b43828ca62f01e113dfcb,
title = "Ageing, oestrogen, platelets and thrombotic risk",
abstract = "1. Adverse thrombotic cardiovascular events increase in women coincident with the onset of menopause. 2. Age past menopause may be an important variable in defining the benefit/risk of hormone treatments. 3. Few studies have examined hormonal status as a variable of ageing using a polygenomic approach of both humoral and cellular components of the coagulation system. 4. Longitudinal studies of a global set of platelet functions that define procoagulant activity (i.e. adhesion, aggregation, secretion and thrombin production) in individuals with documented hormonal status are needed to better understand how hormonal changes associated with ageing impact thrombotic risk.",
keywords = "17β-oestradiol, Energy metabolism, Kronos Early Estrogen Prevention Study (KEEPS), Mitochondria, Women's Health Initiative",
author = "Miller, {Virginia M} and Muthuvel Jayachandran and Owen, {Whyte G.}",
year = "2007",
month = "8",
doi = "10.1111/j.1440-1681.2007.04685.x",
language = "English (US)",
volume = "34",
pages = "814--821",
journal = "Clinical and Experimental Pharmacology and Physiology",
issn = "0305-1870",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Ageing, oestrogen, platelets and thrombotic risk

AU - Miller, Virginia M

AU - Jayachandran, Muthuvel

AU - Owen, Whyte G.

PY - 2007/8

Y1 - 2007/8

N2 - 1. Adverse thrombotic cardiovascular events increase in women coincident with the onset of menopause. 2. Age past menopause may be an important variable in defining the benefit/risk of hormone treatments. 3. Few studies have examined hormonal status as a variable of ageing using a polygenomic approach of both humoral and cellular components of the coagulation system. 4. Longitudinal studies of a global set of platelet functions that define procoagulant activity (i.e. adhesion, aggregation, secretion and thrombin production) in individuals with documented hormonal status are needed to better understand how hormonal changes associated with ageing impact thrombotic risk.

AB - 1. Adverse thrombotic cardiovascular events increase in women coincident with the onset of menopause. 2. Age past menopause may be an important variable in defining the benefit/risk of hormone treatments. 3. Few studies have examined hormonal status as a variable of ageing using a polygenomic approach of both humoral and cellular components of the coagulation system. 4. Longitudinal studies of a global set of platelet functions that define procoagulant activity (i.e. adhesion, aggregation, secretion and thrombin production) in individuals with documented hormonal status are needed to better understand how hormonal changes associated with ageing impact thrombotic risk.

KW - 17β-oestradiol

KW - Energy metabolism

KW - Kronos Early Estrogen Prevention Study (KEEPS)

KW - Mitochondria

KW - Women's Health Initiative

UR - http://www.scopus.com/inward/record.url?scp=34347348973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347348973&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1681.2007.04685.x

DO - 10.1111/j.1440-1681.2007.04685.x

M3 - Article

VL - 34

SP - 814

EP - 821

JO - Clinical and Experimental Pharmacology and Physiology

JF - Clinical and Experimental Pharmacology and Physiology

SN - 0305-1870

IS - 8

ER -